The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Vaseretic
enalapril maleate and hydrochlorothiazide · ENALAPRIL MALEATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 · Tablet · Oral · Bausch Health US, LLC
NDC 00187-0146-01 · 100 TABLET in 1 BOTTLE · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$11.08per dosage unitgross, before rebates — matched by drug name · 2024
- Part D point of sale (median)$12.71per unitnegotiated price across 2 plans — before rebates · Apr 1, 2026
- Medicaid generic ceiling (FUL)$0.5452per TABweighted avg manufacturer price $0.3116 · Apr 1, 2020
Medicare Part D
All Part D pricing →ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$12.71per unit
middle half $12.71–$12.71 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
$7.63–$9.53
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,303.50
Reported to Texas DSHS · 2026 annual filing · Bausch Health US, LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for enalapril maleate and hydrochlorothiazide (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA019221
- TE code
- AB
- Approval date
- Oct 31, 1986
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · TerminatedMay 21, 2014Valeant Pharmaceuticals North America LLC — Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package outset
Manufacturers of enalapril maleate and hydrochlorothiazide (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Sun Pharmaceutical Industries, Inc. | ENALAPRIL MALEATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Jul 16, 2026 | Sep 3, 2026 |
| Sun Pharmaceutical Industries, Inc. | ENALAPRIL MALEATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Jul 16, 2026 | Sep 3, 2026 |
| Bausch Health US, LLC | ENALAPRIL MALEATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Limited | ENALAPRIL MALEATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Limited | ENALAPRIL MALEATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Taro Pharmaceuticals U.S.A., Inc. | ENALAPRIL MALEATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Taro Pharmaceuticals U.S.A., Inc. | ENALAPRIL MALEATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Vaseretic — NDC 00187-0146-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00187014601.
Free to cite with attribution — see how the data is put together.